Initial testing of lenalidomide by the pediatric preclinical testing program

about

A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma.Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy.

P2860

Q36888962-209A989B-B2DF-4FEC-854C-F6FA97A06895 Q37683033-D78ECDD5-FFC9-4D36-B0EE-D0E9FB2B9657

P2860

Initial testing of lenalidomide by the pediatric preclinical testing program

Item

http://www.wikidata.org/entity/Q35861457

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Initial testing of lenalidomide by the pediatric preclinical testing program

@ast

Initial testing of lenalidomide by the pediatric preclinical testing program

@en

type

Item

label

Initial testing of lenalidomide by the pediatric preclinical testing program

@ast

Initial testing of lenalidomide by the pediatric preclinical testing program

@en

prefLabel

Initial testing of lenalidomide by the pediatric preclinical testing program

@ast

Initial testing of lenalidomide by the pediatric preclinical testing program

@en

P1476

Initial testing of lenalidomide by the pediatric preclinical testing program

@en

P2093

Catherine A Billups

http://www.w3.org/2001/XMLSchema#string

Christopher L Morton

http://www.w3.org/2001/XMLSchema#string

E Anders Kolb

http://www.w3.org/2001/XMLSchema#string

Hernan Carol

http://www.w3.org/2001/XMLSchema#string

John M Maris

http://www.w3.org/2001/XMLSchema#string

Malcolm A Smith

http://www.w3.org/2001/XMLSchema#string

Peter J Houghton

http://www.w3.org/2001/XMLSchema#string

Stephen T Keir

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanism of action of lenalidomide in hematological malignancies

Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice

Efficacy of lenalidomide in myelodysplastic syndromes.

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.

P304

606-611

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.22877

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-02-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21360651

http://www.w3.org/2001/XMLSchema#string

P932

4505747

http://www.w3.org/2001/XMLSchema#string

Initial testing of lenalidomide by the pediatric preclinical testing program

about

P2860

P2860

Initial testing of lenalidomide by the pediatric preclinical testing program

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932